Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas

Recruiting now · Not applicable

Conditions studied: Liposarcoma, Atypical Lipomatous Tumor

In brief

The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.

Key facts

Study ID

NCT04224064

Run by

Institut du Cancer de Montpellier - Val d'Aurelle

People needed

158

Starts

2020-08-26

Expected to finish

2029-12-01

Last updated by the study team

2025-02-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma.
• Pregnancy and/or feeding

Where it is running

• Institut du Cancer de Montpellier - Val d'Aurelle — Montpellier, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.